Rivaroxaban is an oral anticoagulant that directly inhibits factor Xa, preventing the conversion of prothrombin to thrombin, the final step in the clotting process, preventing the formation of thrombin and blood clot formation. Anti-Xa assays for rivaroxaban are used to monitor anticoagulant therapy, optimize dosing, ensure therapeutic efficacy, and ensure effective prevention of thrombosis and bleeding complications.

References:

• Song Z, Wu H, Cao H, Yang S, Tang M, Qin L. Routine coagulation test abnormalities caused by rivaroxaban: A case report. Medicine (Baltimore). 2018 November;97(45):e13104. doi: 10.1097/MD.0000000000013104. Accessed on Jan 31st,2024.
• Lindhoff-Last E, Ansell J, Spiro T, Samama MM. Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med. 2013 September;45(5-6):423-9. doi: 10.3109/07853890.2013.801274.Accessed on Jan 31st,2024.
• Data on File: PureLab DOS V5, November 10^th, 2023.